Yttrium-90 Radiation Segmentectomy for Hepatocellular Carcinoma

Part of paid clinical trials in San Francisco, California.

Sponsor
University of California, San Francisco
Study ID
NCT07110233
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
22 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • TheraSphere® Yttrium-90 microspheres — DEVICE
    Administered intra-arterially
  • Health Related Quality of Life Questionnaires (HRQOL) — OTHER
    Surveys administered

Study Details

This is a prospective, single-blinded, single-arm, open-label Phase II trial of trans-arterial radiation segmentectomy using Yttrium-90 glass microspheres (TheraSphere®) for Hepatocellular Carcinoma (HCC) participants with unresectable Barcelona clinic liver cancer (BCLC) stage A disease.

Key Dates

Start date
May 1, 2026
Status verified
Jan 2026
Primary completion
Dec 31, 2028
Completion
Dec 31, 2028

Study Design

Enrollment
64 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC

Arms

  • Experimental: Group 1. TheraSphere® Yttrium-90 microspheres
    Participants with a single tumor measuring 2-5 cm will receive one dose of TheraSphere® \>250 Gy, and ideally \> 400 Gy at the treating physician's discretion. Participants will be monitored for safety and complete quality of life questionnaires.
  • Experimental: Group 2. TheraSphere® Yttrium-90 microspheres
    Participants with 2-3 tumors ≤ 3 cm in diameter (T2 disease) will receive one dose of TheraSphere® \>250 Gy, and ideally \> 400 Gy at the treating physician's discretion. Participants will be monitored for safety and complete quality of life questionnaires.

Primary Outcome Measure

Objective Response Rate (ORR) by mRECIST [ Time Frame: Up to 6 months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of California, San FranciscoSan FranciscoCalifornia94143
Maya Aslam
[email protected]
(415) 514-8987
Ryan Lokken, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in San Francisco, CA

By condition
Liver cancer
By specialty
OncologyGI oncologyHepatology
By research site
University of California, San Francisco· San Francisco, CA

Related Studies